A Novel Therapeutic
We’re creating the first potential treatment for Demodex blepharitis
What is TP-03?
TP-03 is a topical ophthalmic formulation of lotilaner that, if approved, may offer treatment for millions of patients with Demodex blepharitis.1
Up to 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.1-3
TP-03 may change that.
- Designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease–Demodex mite infestation1
- Paralyzes and eradicates Demodex mites by selectively inhibiting parasite-specific GABA-Cl channels1
- Evaluated in the pivotal Saturn-1 (Phase 2b/3) trial involving 421 patients and met all primary and secondary endpoints with no serious treatment-related adverse events and no treatment-related discontinuations1
- Second pivotal Phase 3 trial, Saturn-2 underway, with results expected in Q1 2022 and the potential to be the first FDA-approved therapeutic and standard of care for the treatment of Demodex blepharitis
The active ingredient in TP-03 is lotilaner, a well-characterized anti-parasitic agent that targets parasite-specific GABA-CI channels.1
Saturn-1 Phase 2b/3 Pivotal Trial
References:
1. Tarsus Pharmaceuticals, Inc. announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis. Tarsus Pharmaceuticals, Inc. Press release. June 21, 2021. 2. Sadri E, Yeu E, Trattler W, Holdbrook M, Baba S. The prevalence of collarettes and Demodex blepharitis in ophthalmology and optometry practices. Presented at: ASCRS 2021. Abstract 75009. 3. Wilson FA, Stimpson JP, Wang Y. Inconsistencies exist in the national estimates of eye care services utilization in the United States. J Ophthalmol. doi:10.1155/2015/435606.
15440 Laguna Canyon Road, Ste 160
Irvine, CA 92618
2021 Tarsus Pharmaceuticals, Inc. All rights reserved.
TARSUS and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
Contact Tarsus
Please reach out to us using the form below.